Admission of a major data error in previous roxadustat presentations leaves the novel anaemia pill’s future in doubt.
The group discontinues its first-generation antisense Huntington’s projects on disappointing efficacy, leaving its next-gen asset with much to prove.
But the company focused on a modified intent-to-treat analysis of its pivotal trial.
The group’s antisense project is the only game in town for Usher syndrome, but its latest trial is not a slam-dunk.
With results of the full primary analysis now out the spotlight falls on a further 14 as yet unadjudicated Covid-19 cases.
A radioligand acquired as part of a $2.1bn deal – and which the sellside believes to be Novartis’s most valuable R&D asset – hits in phase III.
The company placed part of the blame for its mid-stage hearing loss failure on subjects exaggerating their level of hearing loss.
AZD1222 could be rehabilitated by US pivotal trial data showing efficacy of 79%, with no worries about blood clots.
Pivotal data on its closed-loop insulin delivery system look good, but Medtronic remains a threat.